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Abstract
Backgroud The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year
biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP)
followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes by using a combined-intensified-
modulated-adjuvant treatment, including RT and hormone therapy (HT) after RP.
Materials and methods This phase I/II trial treatment was designed to improve 5-year bDFS from ~ 75 to 90%. Patients
were consecutively enrolled using the following inclusion criteria: age < 80 years, histological diagnosis of prostate ade-
nocarcinoma without known metastases, stage pT2-4N0-1, and Eastern Cooperative Oncology Group performance status of
0–2. All patients had at least one of these pathologic features: capsular perforation, positive surgical margins, seminal vesicle
invasion, and pelvic lymph nodes involvement. A minimum dose of 64.8 Gy to the tumor bed was delivered in all patients.
Depending on tumor characteristics at diagnosis, patients received a higher dose (70.2 Gy; 85.4%) and/or prophylactic pelvic
lymph nodes irradiation (57.7%) and/or HT (69.1%). Biochemical relapse was defined as two consecutive rising prostate-
specific antigen (PSA) values > 0.2 ng/ml.
Results A total of 123 patients were enrolled in the study and completed the scheduled treatment. Median preoperative and
postoperative PSA were: 8.8 and 0.06 ng/mL, respectively. The percentages of patients with pathologically involved nodes
and positive resection margins were: 14.6% and 58.5%, respectively. With a median follow-up of 67 months (range:
37–120 months), the actuarial 5-year bDFS, local control, metastasis-free survival, and overall survival (OS) were: 92.9%,
98.7%, 96.1%, and 95.1%, respectively.
Conclusion A higher 5-year bDFS (92.9%) was recorded compared to studies based on standard adjuvant RT, even though
patients with nodal disease and detectable postoperative PSA were enrolled. Clinical end points, as long-term disease-free
survival and OS, will require further assessments. (ClinicalTrials.gov: NCT03169933)
Introduction
Despite a progressive decrease in mortality rates, prostate
cancer (PCa) still represents the third cause of cancer-
related death in Europe [1]. Radical prostatectomy (RP) is
an effective treatment for localized PCa. Nevertheless, a
significant percentage of patients (15–60%) develop recur-
rences after surgery and therefore require salvage radio-
therapy (RT) [2–8]. Several randomized studies have
demonstrated the benefit of adjuvant RT after RP in selected
patients at high risk of failures [3–5].
An improvement in biochemical disease-free survival
(bDFS) was first reported by EORTC 22,911 trial in 2005
[9]. The rate of biochemical failure remained significant
(25% after 5 years). Based on the results of that study, we
hypothesized that RT dose escalation to tumor bed, pelvic
lymph node irradiation (PNI) in selected patients with
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higher risk of regional failures, and adjuvant hormone
therapy (HT) for those with a higher risk of distant metas-
tases could further reduce the recurrence rates.
In fact, with a dose higher than 60 Gy on prostatic and
seminal vesicles bed, an improved bDFS was previously
recorded [10]. In addition, patients at high risk of local
failures such as those with positive surgical margins and/or
perineural invasion may benefit from further increased
doses (up to 70.2 Gy), to minimize recurrence rates [11, 12].
PNI may also reduce regional recurrences in selected
patients at high risk for nodal involvement [13]. In fact,
some studies have demonstrated an improved bDFS after
prophylactic nodal irradiation also in post-prostatectomy
setting [14–16]. Furthermore, improved bDFS in patients
with a high risk of recurrence after RP with the combination
of adjuvant HT and RT have been reported [17, 18].
Thus, considering all these factors, we defined
combined-intensified-modulated-adjuvant (CIMA) treat-
ment, as a new modality that may potentially improve
patients’ outcome, by selectively using RT dose escalation,
PNI, and HT based on individual patient risks after RP. The
feasibility of CIMA has been previously tested in a pre-
liminary analysis [19]. We now report the long-term out-
comes of this study.
Materials and methods
Study objectives
The primary trial objective was to test the possibility to
improve 5-year bDFS from 75 to 90%, as calculated from
date of surgery to biochemical relapse. Biochemical relapse
was defined as two consecutively rising prostate-specific
antigen (PSA) values and a PSA level > 0.2 ng/mL. Sec-
ondary end points included early and delayed treatment-
related side-effects, local control (LC), and metastasis-free
survival (MFS). Patients without the events of interest were
censored at their last contact date (last PSA assessment).
Study design
A phase I/II trial was planned. A previously published ran-
domized study [9] showed 75% 5-year bDFS in patients
treated with standard adjuvant RT (dose: 60 Gy, no PNI, no
HT). Considering 90% as the true success rate for our
experimental cohort, 100 experimental patients were needed
to reject the null hypothesis, that the success rates for CIMA
and historical patients are equal with probability (power) 0.8.
The 0.05 type I error probability is associated with the test of
this null hypothesis. An uncorrected χ2 statistic was used to
evaluate this null hypothesis. Some over-recruitment was
planned to compensate for 20% drop-out after enrollment.
Inclusion criteria
Patients < 80 years, with resected non-metastatic PCa not
previously treated with RT, HT, or chemotherapy (CT) and
free from surgical complications were enrolled. Further-
more, patients had at least one of the following risk factors:
extracapsular extension, and/or positive surgical margins,
and/or seminal vesicle infiltration, and/or regional lymph
nodes invasion. Undetectable postoperative PSA was not
considered as an inclusion criterion for the study. We used
the International Union Against Cancer criteria [20] to
define tumor stages. All patients were evaluated by PSA
(preoperative and postoperative), abdominal and pelvic CT
or MRI, and bone scans prior to enrollment. Patients with
distant metastases, extra-pelvic lymphadenopathies, and
macroscopic residual disease were excluded. All patients
had an Eastern Cooperative Oncology Group (ECOG)
performance status between 0 and 2, and adequate bone
marrow function (hemoglobin concentration > 8 g/dl, white
blood cell count > 3000/mm³, platelet count > 75,000/mm³).
Therapy
Radiotherapy
The details of the three-dimensional (3D) conformal RT
technique were described in our previous report [19]. Prior
to the planning scans, all patients were given detailed
instructions about positioning (supine) and bladder and
bowel filling to attain reproducibility during simulation and
throughout RT administration. Based on Radiation Therapy
Oncology Group (RTOG) guidelines for the definition of
the clinical target volume in postoperative conformal RT,
we defined two CTVs: CTV1 and CTV2. CTV1 included
the prostate and seminal vesicles bed, whereas CTV2
included obturator, internal iliac, external iliac, and pre-
sacral (above S2–S3) nodes.
All patients received postoperative RT with set-up eva-
luation and correction if needed (using Electronic Portal
Imaging Device) daily, 5 days a week. We used the Inter-
national Commission of Radiation Unit 62 guidelines [21]
for dose specification and in consideration of tumor char-
acteristics (Table 1), doses were prescribed accordingly: (i)
PNI (45 Gy; 1.8 Gy/fraction) plus boost to the prostate bed
(19.8–25.2 Gy; 1.8 Gy/fraction; total dose: 64.8–70.2 Gy) or
(ii) exclusive prostate bed irradiation (64.8–70.2 Gy; 1.8
Gy/fraction).
Hormone therapy
Table 1 reports HT prescriptions. At commencement of
adjuvant RT, patients started either LH-RH analog (leu-
prorelin, 11.25 mg every 3 months, intramuscularly) or
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antiandrogen agent (bicalutamide, 150 mg daily per os).
Based on risk factors (T stage and Gleason score (GS), to
the patients were prescribed short time (6 months) or long
time (24 months) HT.
Statistical analysis
A descriptive analysis of the sample was carried out using
mean and standard deviation for continuous variables,
whereas absolute and relative frequencies for qualitative
ones. Patients were monitored weekly during RT. Acute
side-effects were scored according to the RTOG scale [22].
Late complications were assessed with the Late Radiation
Morbidity Scoring Scheme of the RTOG/European Orga-
nization for Research and Treatment of Cancer (EORTC)
[22]. Clinical assessment included serum PSA level and
digital rectal exam every 3 months for the first 2 years,
biannually in 3rd, 4th, and 5th years, and annually thereafter.
Additional studies such as bone scans or CT/MRI were
requested if there were clinical suspicions of recurrences or
increasing PSA levels. Analyzed variables were: age at
diagnosis (≤ 65 vs. > 65), pathological evaluation on the
extent of the primary tumor (pT2 vs. pT3–4), pathological
evaluation of regional lymph nodes (pN0 vs. pN1 vs. pNx),
margin status (R0 vs. R1), perineural infiltration (no vs. yes),
PSA pre-surgery (≤ 10 ng/mL vs. > 10 ng/mL), PSA post
surgery (≤ 0.2 ng/mL vs. > 0.2 ng/mL), histopathologic
grade (GS ≤ 7 vs. GS 8–10), lymphadenectomy (no vs. yes),
surgical bed dose (64.8 vs. 70.2 Gy), PNI (no vs. yes), HT
(no vs. yes), type of HT (antiandrogen vs. LH-RH analog),
and duration of HT (short-term: 6 months vs. long time:
24 months). We evaluated the impact of these factors on
bDFS. Furthermore, analysis of bDFS, LC, MFS, and
overall survival (OS) was performed. Survival curves were
calculated with the Kaplan–Meier product-limit method and
stratifications for selected prognostic factors were assessed
for statistical significance using the log-rank test statistic
[23, 24]. Statistical analysis was carried out using SYSTAT,
version 11.0 (SPSS, Chicago, IL). A two-sided p value of
0.05 was considered statistically significant.
Ethical issues
All patients consented to treatment and provided a written
informed consent to enrollment in the clinical trial. Our
institutional review board approved the study. Patients were
enrolled from 2004 to 2009. The study is registered in an
international public registry (ClinicalTrials.gov Identifier:
NCT03169933).
Results
Median follow-up was 67 months (range 37–120 months).
Figure 1 illustrates the Consolidated Standards of Reporting
Trials (CONSORT) diagram. Patients and treatment char-
acteristics are listed in Table 2. Histologically proven
regional lymph nodes invasion (pN1) was 18 (14.6%).
Bladder and rectum tumor invasion (pT4) was recorded in
four (3.3%) patients. Detectable PSA level (> 0.2 ng/mL)
was recorded in nine (7.3%) patients. Five-year LC, MFS,
and OS were: 98.7%, 96.1%, and 95.1%, respectively.
Actuarial 5-year and 10-year bDFS were 92.9% and 75.8%,
respectively (Fig. 2). There was a significant difference
between patients with GS ≤ 7 vs. GS > 7 (5-year bDFS:
95.5% vs 78.3 %; p= 0.001) (Table 3, Fig. 3). This dif-
ference maintained statistical significance (p= 0.014) even
after Bonferroni’s correction for multiple comparisons.
Grade 1–2 and Grade 3 acute GI toxicities were recorded in
56 (45.6%) and 3 (2.4%) patients, respectively. Grade 1–2
acute GU toxicities were recorded in 59 (48.0%) patients
Refused to participate (n = 7) 
Refused only adjuvant hormonal therapy (n = 5) 
Refused adjuvant therapy (n = 2)
Patients evaluated 
(n = 154) 
Did not meet the inclusion criteria (n = 24) 
Due to inadequate stage or margin status (n = 23) 
Had previous pelvic radiotherapy (n = 1) 
Eligible (n = 130) 
Enrolled and analysed 
(n = 123) 
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT)
diagram
Table 1 Prescribed treatment based on patients/tumor characteristics
Treatment modulation Patients/tumor characteristics
Higher dose (70.2 Gy) to the
tumor bed
Positive surgical margins and/or
perineural infiltration and/or
postoperative PSA> 0.2 ng / mL
PNI pN1 and/or
lymph node risk > 15% a and < 10
resected nodes and/or
Gleason score > 7
Short-term (6 months) HT pT > 2 and/or
Gleason score = 7
Long-term (24 months) HT pN1 and/or
preoperative PSA > 20 ng/mL and/or
Gleason score > 7
aBased on Roach 3rd M (Roach 1993); HT: hormone therapy; PNI:
prophylactic nodal irradiation; PSA: prostate-specific antigen.
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and Grade 3 GU toxicity in 4 (3.3%) patients, respectively.
No patient had Grade 4 acute toxicity. Grade 1 and 2 late GI
toxicities were recorded in 15 (12.2%) and 5 (4.1%)
patients, respectively. No patient had Grade ≥ 3 GI
toxicities. Five-year survival free from Grade 1 and
Grade 2 GI toxicities were 87.0% and 96.7%, respectively.
Grade 1, Grade 2, and Grade 3 late GU toxicities
were recorded in 22 (17.9%), 16 (13.0%), and 5 (4.1%)
patients, respectively. Five-year survival free from Grade 1,
Grade 2, and Grade 3 GU toxicities were 78.6%, 88.6%,
and 95.0%, respectively. No significant differences in terms
of Grade ≥ 2 GU and GI toxicities were recorded based
on dose to prostate bed, PNI, and adjuvant HT (data not
shown).
Discussion
To our knowledge, this is the first prospective study sug-
gesting the possibility to achieve higher bDFS rates by
using a tailored treatment after RP for localized PCa.
Despite poor prognostic features such as high rates of
positive margins and perineural invasion, and inclusion of
patients with pathologically involved pelvic nodes, our
bDFS seems significantly higher (92.9%) compared with
EORTC trial 22,911 [5] and other randomized trials with a
biochemical recurrence rate of ~ 25% [3, 4]. Therefore, we
could hypothesis that CIMA may improve patient outcomes
by a combination of factors as discussed below. Obviously,
this conclusion should be considered with caution, as (i) our
study was a single arm trial, (ii) the apparent improvement
of the results derives from a comparison with different
studies. Therefore, we cannot rule out if the “Gleason grade
migration” phenomena could have influenced on our com-
parisons result. In the EORTC 22,911 trial [9], for example,
patients were enrolled between 1992 and 2001, clearly
earlier compared with our study (2004–2009). Furthermore,
comparing our experience with previous studies, we need to
consider the RT technological evolution in recent years,
which could have also influenced on the results. From the
above-mentioned trial of Bolla et al. [9], RT was delivered
Table 2 Patients and treatment characteristics
No. %
All patients 123 100
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N number of patients; PSA prostate-specific antigen
Fig. 2 actuarial biochemical progression-free survival
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with 2D technique, whereas in our study, 3D conformal
technique was used.
When we analysed the three reported randomized studies
[3–5] with radiation doses ranging from 60 to 64 Gy, most
of our patients (85.4%) received a significantly higher dose
(70.2 Gy) to the tumor bed. In addition, patients at risk of
pelvic failures underwent PNI, which may be the reason of
lower regional recurrences rate at this site, contrary to other
studies. We believe that a combination of higher radiation
doses with selective PNI may explain the comparable bDFS
among patients with R0 vs. R1, and pN1 vs. pN0 disease,
respectively. Furthermore, our results suggest the possibility
to achieve an improved outcome after PNI compared with
prostate irradiation alone as reported in other analyzes
[14–16] in patients with metastatic pelvic nodes or high
pelvic failure risk. It is noteworthy that, despite a higher
tumor dose and selective PNI, the rate of acute and long-
term toxicity was very low. Table 4 summarizes the results
of randomized trials on postoperative RT in comparison
with our series. Although, Table 4 clearly shows that the
present study achieved a higher 5-year bDFS, we
acknowledge the difficulties in comparing these results
directly. In fact, our series has the highest rate of patients
with lymph node metastases and high Gleason score, but at
the same time the lower rate of R1 patients, whereas the
proportion of patients with pre-surgical PSA > 10 ng/ml is
poorly comparable and that of patients with post-surgical
PSA > 0.2 ng/ml is similar to that of randomized trials.
Other non-randomized studies using higher than standard
dose ± HT and PNI were published [25–28]. Table 5 sum-
marizes the results of these series compared with our trial.
Although it is difficult to compare those series owing to
heterogeneity in terms of margin status and pathological
nodal stage, some of these studies seem to confirm that RT
dose escalation in high-risk patients after RP may improve
bDFS. Cozzarini and colleagues [25] reported 83.0% and
Table 3 Impact of patient, tumors, and treatment parameters on 5
years biochemical disease-free survival (univariate analysis)
No. % 5-year bDFS (%) p
Age, years
≤65 72 58.5 92.0 0.166
>65 51 41.5 93.9
pT
2 17 13.8 92.3 0.515
3–4 106 86.2 93.2
pN
0 79 64.2 93.6 0.674
1 18 14.6 90.0
X 26 21.1 91.3
Margins status
R0 51 41.5 93.1 0.441
R1 72 58.5 92.9
Perineural infiltration
No 47 38.2 93.9 0.115
Yes 76 61.8 92.6
PSA pre-surgery, μg/L
≤ 10 69 56.1 92.0 0.391
> 10 54 43.9 93.9
PSA (post surgery), μg/L
≤ 0.2 114 92.7 93.2 0.602
> 0.2 9 7.3 88.9
Histopathologic grade, Gleason score
≤ 7 92 74.8 95.5 0.001
8–10 31 25.2 85.5
Lymphadenectomy
No 26 21.1 91.3 0.499
Yes 97 78.9 93.3
Radiotherapy dose to prostatic bed, Gy
64.8 18 14.6 91.7 0.543
70.2 105 85.4 93.1
Prophylactic nodal irradiation
No 52 42.3 96.2 0.273
Yes 71 57.7 90.3
Adjuvant hormone therapy
No 38 30.9 91.3 0.486
Yes 85 69.1 93.7
Adjuvant hormone therapy
Bicalutamide 48 39.0 92.7 0.611
LH-RH analog 37 30.1 94.1
Adjuvant hormone therapy
Short-term (6 months) 23 27.1 100.0 0.183
Long-term (24 months) 62 72.9 91.8
bDFS biochemical disease-free survival, N number of patients, PSA
prostate-specific antigen
The bold entry was to emphasis the significant p valve
Fig. 3 impact of Gleason Score on biochemical progression-free
survival
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71.0% 5-year bDFS in patients receiving higher and lower
than 70.2 Gy RT dose, respectively. This positive impact of
dose escalation was also observed in R1 patients [27].
Furthermore, Ost et al. [25], prescribing a dose of 70–77
Gy, reported, 84% 7-year bDFS.
The influence of HT on bDFS after RP is difficult to
assess owing to the variations in patients’ selection among
retrospective studies [25–28]. We observed no significant
effect of HT on bDFS in our study (5-year bDFS: 91.3% vs
93.7% in patients not receiving or receiving HT, respec-
tively; p 0.486). We could hypothesize that this lack of
advantage is due to HT prescription inhomogeneity. Indeed,
the use of both androgen deprivation therapy and anti-
androgen treatment (high-dose bicalutamide) may represent
a limitation of our study. However, when CIMA trial was
planned, the standard policy in our center was to inform
patients on available evidence and different side-effects of
both HTs and to let them choose. Furthermore, we did not
observe any differences between the two HTs in terms of
bDFS. Therefore, we postulated that the lack of response to
HT may have been due to selective prescription and mod-
ulation based on risk factors, with HT prescribed only to
higher risk subjects.
More generally, the advantages of combining post-
operative RT with adjuvant HT after RP has been pre-
viously demonstrated. One study reported improved
survival in patients with positive pelvic nodes who received
both adjuvant HT and postoperative RT compared with
patients receiving adjuvant HT alone [29]. Furthermore, a
randomized trial showed that adjuvant systemic therapy
based on high-dose bicalutamide may improve survival in
patients treated with salvage RT after biochemical recur-
rence [30].
Despite the advantage of combining RT and HT in the
adjuvant treatment of high-risk patients, the outcome of
patients with high GS remains poorer. In our trial, a GS of
8–10 was correlated with lower bDFS and MFS compared
with patients with GS 6–7. Other systemic therapies such as
CT could be useful for these patients with higher risk of
metastases. For example, in the setting of not-resected high-
risk PCa, Fizazi et al. [31] reported a significant improve-
ment of bDFS by combining CT to HT, compared with HT
alone. Therefore, prospective trials to investigate the addi-
tion of CT to adjuvant treatment of high-risk PCa seem
justified.
Unfortunately, being a single arm trial, our study is not
able to provide information on the important problem of
selecting patients for adjuvant therapies. However, we
believe that our study has important clinical implications.
Our results suggest that CIMA may improve bDFS by
selective use of dose escalation, PNI, and adjuvant HT, with
reasonable complications rates. Prospective clinical trials
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to further reduce the risk of systemic relapses should be
designed. These trials should be planned to enroll patients
with high risk of systemic relapses, particularly patients
with high GS.
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